Market Cap | 11.48M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -1.48M | Forward P/E | -0.84 | EPS next Y | - | 50D Avg Chg | -6.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
Dividend | N/A | Price/Book | 1.27 | EPS next 5Y | - | 52W High Chg | -67.00% |
Recommedations | 1.50 | Quick Ratio | 7.08 | Shares Outstanding | 2.90M | 52W Low Chg | 56.00% |
Insider Own | 3.20% | ROA | -33.14% | Shares Float | 2.64M | Beta | -0.15 |
Inst Own | 6.37% | ROE | -29.36% | Shares Shorted/Prior | 67.79K/463 | Price | 0.64 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 44,048 | Target Price | 12.11 |
Oper. Margin | - | Earnings Date | Nov 12 | Volume | 7,556 | Change | 0.54% |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.